Lenacapavir was approved for medical use in the European Union in August 2022,[10][12] in Canada in November 2022,[5][6] and in the United States in December 2022.[11][13][14] It is the first of a class of drugs called capsid inhibitors to be FDA-approved for treating HIV/AIDS.[11][15]
for treatment dosage price is 42k/year but presumably preventive dose is smaller
already approved
for treatment dosage price is 42k/year but presumably preventive dose is smaller